Related references
Note: Only part of the references are listed.Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Elisa Agostinetto et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Francesca Carlino et al.
CANCERS (2022)
Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model
Vahid Khaki Bakhtiarvand et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Guillermo Arturo Valencia et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical trials of immunotherapy in triple-negative breast cancer
Frederick M. Howard et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Qiqun Zeng et al.
SCIENCE (2022)
Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice
James D. Barnett et al.
CANCERS (2022)
Immunology and immunotherapy in breast cancer
Vladimir Semiglazov et al.
CANCER BIOLOGY & MEDICINE (2022)
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo et al.
FRONTIERS IN ONCOLOGY (2022)
Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer
Reza Mehdizadeh et al.
CANCERS (2021)
Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model
Sadiya Parveen et al.
MOLECULAR ONCOLOGY (2021)
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
James Isaacs et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Cancer statistics for the year 2020: An overview
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment
Xiaowei Wang et al.
CANCERS (2021)
Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway
Kevin Alicea-Torres et al.
NATURE COMMUNICATIONS (2021)
Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling
Jiale An et al.
ONCOIMMUNOLOGY (2021)
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
TNFR2+TILs are significantly associated with improved survival in triple-negative breast cancer patients
Maya Dadiani et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The premise of personalized immunotherapy for cancer dormancy
Masoud H. Manjili
ONCOGENE (2020)
A QSP model of prostate cancer immunotherapy to identify effective combination therapies
Roberta Coletti et al.
SCIENTIFIC REPORTS (2020)
Triple-negative breast cancer therapy: Current and future perspectives (Review)
Kwang-Ai Won et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Yufei Wang et al.
CANCERS (2020)
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Zhao-hua Gao et al.
BMC CANCER (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
Advances in Targeted Therapies for Triple-Negative Breast Cancer
Kelly E. McCann et al.
DRUGS (2019)
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Livingstone Fultang et al.
EBIOMEDICINE (2019)
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Milica Nedeljkovic et al.
CELLS (2019)
Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer
Xuelei Ma et al.
FRONTIERS IN ONCOLOGY (2019)
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Qiang Lan et al.
ONCOGENE (2019)
CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB
Ya-Ling Hsu et al.
BREAST CANCER RESEARCH (2019)
Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs
Momir Bosiljcic et al.
BREAST CANCER RESEARCH (2019)
An Agent-based Model for Investigating the Effect of Myeloid-Derived Suppressor Cells and its Depletion on Tumor Immune Surveillance
Armin Allahverdy et al.
JOURNAL OF MEDICAL SIGNALS & SENSORS (2019)
Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies
Seyed Peyman Shariatpanahi et al.
JOURNAL OF THEORETICAL BIOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
Xiulan Lai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming et al.
FRONTIERS IN IMMUNOLOGY (2018)
Is adaptive therapy natural?
Frederic Thomas et al.
PLOS BIOLOGY (2018)
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines
Sruthi Ravindranathan et al.
BREAST CANCER RESEARCH (2018)
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
Kenji Gonda et al.
ONCOLOGY LETTERS (2017)
Myeloid cells in circulation and tumor microenvironment of breast cancer patients
Salman M. Toor et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis
Ke Wang et al.
ONCOTARGET (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model
Ana C. Gregorio et al.
PLOS ONE (2016)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth
Sebastien Benzekry et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Does the immune system naturally protect against cancer?
Alexandre Corthay
FRONTIERS IN IMMUNOLOGY (2014)
Myeloid-derived suppressor cells in breast cancer
Joseph Markowitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer
Robert Wesolowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Minu K. Srivastava et al.
PLOS ONE (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Girieca Lorusso et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment
Diego O. Croci et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
C De Giovanni et al.
CANCER RESEARCH (2004)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)